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Abstract
Background: To investigate whether flow-mediated dilation (FMD) impairment, which precedes overt
atherosclerosis, is associated with silent myocardial ischemia (SMI) and asymptomatic coronary artery disease (CAD)
in type 2 diabetes.
Methods: Forearm FMD was measured by ultrasonography in 25 healthy control, 30 non-diabetic overweight or
obese patients and 118 asymptomatic type 2 diabetic patients with a high cardiovascular risk profile. SMI (abnormal
stress myocardial scintiscan and/or stress dobutamine echocardiogram) and CAD (coronary angiography in the
patients with SMI) were assessed in the diabetic cohort.
Results: FMD was lower in diabetic patients (median 0.61% (upper limits of first and third quartiles −1.22;3.2)) than
in healthy controls (3.95% (1.43;5.25), p < 0.01) and overweight/obese patients (4.25% (1.74;5.56), p < 0.01). SMI was
present in 60 diabetic patients, including 21 subjects with CAD. FMD was lower in patients with SMI than in those
without (0.12% (−2.3;1.58) vs 1.64% (0;3.69), p < 0.01), with a higher prevalence of paradoxical vasoconstriction
(50.0% vs 29.3%, p < 0.05). FMD was also lower in patients with than without CAD (−1.22% (−2.5;1) vs 1.13%
(−0.4;3.28), p < 0.01; paradoxical vasoconstriction 61.9% vs 34.4%, p < 0.05). Logistic regression analyses considering
the parameters predicting SMI or CAD in univariate analyses with a p value <0.10 showed that paradoxical
vasoconstriction (odds ratio 2.7 [95% confidence interval 1.2-5.9], p < 0.05) and nephropathy (OR 2.6 [1.2-5.7],
p < 0.05) were independently associated with SMI; and only paradoxical vasoconstriction (OR 3.1 [1.2-8.2], p < 0.05)
with CAD. The negative predictive value of paradoxical vasoconstriction to detect CAD was 88.7%.
Conclusions: In diabetic patients, FMD was independently associated with SMI and asymptomatic CAD.
Trial registration: Trial registration number NCT00685984.
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Background
Type 2 diabetes is associated with a high prevalence of
coronary artery disease (CAD) and with a 2- to 4-fold in-
crease in silent myocardial ischemia (SMI) as compared
with the non diabetic population [1,2]. SMI has been re-
ported in 7 to 65% of the diabetic population [3], this
prevalence increasing with male gender, ageing, longer
duration of diabetes and the presence of additional car-
diovascular risk factors, nephropathy, retinopathy and
peripheral or carotid occlusive arterial disease [1-4]. SMI
is a strong predictor of future coronary events and pre-
mature death [5,6], providing a significant additional
value compared to routine cardiovascular risk assessment
[7].
Endothelial dysfunction is an early phenomenon dur-
ing diabetic atherogenesis [8,9] and has been associated
with a poor cardiovascular prognosis in the diabetic
population [10-12]. Therefore, peripheral endothelial
dysfunction is considered as an integrator of cardiovas-
cular risk. The association between endothelial and
smooth muscle dysfunction evaluated by flow-mediated
dilation (FMD) and SMI in patients with type 2 diabetes
has been previously studied. Some authors did not find
any association but reported a high negative predictive
value for SMI when the endothelial function was normal
[13], whereas others reported a higher prevalence of
SMI in the patients with abnormal FMD [14]. However,
these series included a limited number of subjects,
whose a priori cardiovascular risk was lower than what
has been recommended for SMI screening [2,15]. Fur-
thermore, the patients’ coronary status was unknown in
these studies, with no opportunity to evaluate the poten-
tial association between endothelial function and SMI
according to the presence or the absence of CAD. This
could be crucial as the patients with SMI but no CAD
on angiography are likely to have functional vascular dis-
orders such as abnormal coronary reserve or coronary
endothelial dysfunction [16]. Finally, non-diabetic con-
trol subjects and non-diabetic overweight or obese pa-
tients were not included in these studies. If FMD has
been shown to be lower in patients with type 2 diabetes
than in age- and sex-matched subjects, BMI was higher
in the former [17] and it is known that obesity is associ-
ated with endothelial dysfunction [18]. Thus, there is a
need for further studies to validate the technique and
evaluate the proper impact of diabetes instead of the
combined effect of obesity with diabetes.
We raised the hypothesis that FMD would be impaired
in the diabetic patients, with incremental impairment in
those without SMI, those with SMI but no CAD and
those with both SMI and CAD. The aim of the study
was to investigate in a series of type 2 diabetic patients
with a high cardiovascular risk according to the joint
guidelines of the French Language Association for the
Study of Diabetes and Metabolic Diseases (ALFEDIAM)
and the French Society of Cardiology (SFC) if FMD was
associated with SMI and/or asymptomatic CAD.
Methods
Participants
We recruited control subjects, non-diabetic obese sub-
jects and type 2 diabetic patients in the Department of
Diabetology of Jean Verdier Hospital (Bondy, France).
The study was approved by the Ethical Committee of
Aulnay-sous-Bois, France, and each enrolled patient gave
informed consent (NCT00685984). Control subjects were
free of known diabetes and had no cardiovascular risk
factors. Obese subjects had neither known diabetes nor
diabetes detected on oral glucose tolerance test nor any
history of angina or myocardial infarction and had a nor-
mal resting ECG although they could have other cardio-
vascular risk factors. Eligibility criteria for type 2 diabetic
patients included no history of myocardial infarction or
angina pectoris, normal 12-lead resting ECG, and at least
one of the ALFEDIAM-SFC criteria [2]: (i) patients over
the age of 60 years or with diabetes for more than 10 years
and with at least two or more of the following cardiovascu-
lar risk factors: dyslipidemia (total cholesterol > 6.5 mmol/l
and/or LDL-cholesterol > 4.1 mmol/l, HDL-cholesterol <
0.9 mmol/l, triglycerides > 2.3 mmol/l and/or lipid lowering
medication), hypertension (systolic/diastolic blood pres-
sure ≥ 140/90 mmHg or anti-hypertensive therapy), active
smoking or cessation for less than three years and major
cardiovascular event before the age of 60 years in a first de-
gree relative; (ii) patients, irrespective of their age or level
of classical risk factors, presenting with either periph-
eral or carotid occlusive arterial disease (stenosis mea-
sured 50% by ultrasound examination performed in
each patient) or macroproteinuria (urinary protein ex-
cretion rate ≥0.3 g/24 hours); (iii) patients, irrespective
of their age, with microalbuminuria (urinary albumin excre-
tion rate > 30 mg/day on at least two measurements) and at
least two other classical risk factors; (iv) patients over the
age of 45 years resuming sports activities after sedentary
lifestyle. Exclusion criteria included congenital heart
disease, pregnant women, congestive heart failure or
known cardiopathy, renal insufficiency (creatinine clear-
ance < 60 ml/min) and Raynaud syndrome.
Cardiovascular investigations
Peripheral endothelial function
We evaluated FMD on the brachial artery as recom-
mended by Coretti et al. Patients were explored in the
supine position 24 hours after withdrawal of vasodilators
and were instructed to avoid caffeine-containing prod-
ucts, smoking and exercise for at least twelve hours
before the exploration [19]. Ultrasound images were ob-
tained in the longitudinal plane using a high-resolution
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10.0 MHz linear array transducer (Siemens Acuson se-
quoia C512). A blood pressure cuff was placed around
the forearm, distal of the artery segment that was ex-
plored, and was inflated 50 mmHg above the patient’s sys-
tolic blood pressure for 5 minutes. A single investigator
(IP) recorded the brachial artery diameter and flow vel-
ocity by 2D echography and pulsed Doppler at baseline, at
deflation and 1 minute after deflation [19]. An angulation
of the probe <60° was carefully sought. Analyses were per-
formed off-line and blinded to test conditions and patient
identity. Diameter measurements were done at teledias-
tole. FMD was calculated as the percentage of increase (+)
or decrease (−, which depicted paradoxical vasoconstric-
tion) in the artery diameter from baseline to 1-minute
after deflation. The diameter was calculated as the
mean of at least 3 measurements manually performed
with electronic calipers at end-diastole determined
with simultaneous ECG recording. The intra-individual
variability was tested in ten patients at one-hour inter-
val. The intra-individual agreement index [20] was
0.04 and 0.04 for the artery diameter measurement at
baseline and at 1 minute, respectively and repeatability
coefficient was 0.09 cm and 0.06 cm respectively.
Screening for SMI
Each diabetic patient was planned to undergo both a
myocardial scintigraphy and a stress echocardiography.
The thallium 201 myocardial scintigraphy was per-
formed after an ECG stress test, or a pharmacological
stress test (dipyridamole injection), or both. The ECG
stress test was performed in patients who could exercise
on a bicycle ergometer and could be expected to have an
interpretable exercise-ECG. When the patient was un-
able to exercise or when the ECG stress test result was
indeterminate, a pharmacological stress test using dipyr-
idamole was carried out [4,7,21]. Target heart rate was
defined as 85% of maximal predicted heart rate (220-
age). An abnormal scintigraphy imaging was defined as
defects in at least 3 out of 17 segmental regions. Briefly,
stress dobutamine echography was performed according
to a protocol using 3-min stages with incremental dobu-
tamine doses from 10 to 40 μg/kg/min and atropine, up
to a total dose of 1 mg, as needed to increase the heart
rate up to 85% of the predicted maximal heart rate.
An abnormal stress dobutamine echocardiogram was
defined by the presence of fixed akinetic or dyskinetic
segment(s) and/or by the worsening or the development
of a new wall motion abnormality, including a deterior-
ation of wall motion after an initial improvement at
low-dose dobutamine, in more than 2 concordant seg-
ments in a 17-segment model of the left ventricle. SMI
was defined as an abnormal ECG stress test and/or ab-
normal myocardial scintiscan and/or abnormal stress
echocardiogram.
Screening for CAD
A selective coronary angiography was performed in the
diabetic patients with SMI within a period of 2 months
after the noninvasive investigation. CAD was defined as
a 70% narrowing of the luminal diameter in the left an-
terior descending artery, the circumflex artery, a well-
developed marginal vessel or the right coronary artery,
or as a 50% diameter narrowing of the left main coron-
ary artery.
Biochemical assays
The following measurements were recorded at the time
of screening for SMI: HbA1c (Dimension® technology,
Siemens Healthcare Diagnosis Inc., Newark, USA), fast-
ing glucose value measured on venous plasma by the
glucose oxydase method (colorimetry, Kone Optima,
Thermolab System), serum total cholesterol, HDL chol-
esterol and triglycerides (enzymatic colorimetry, Hitachi
912, Roche Diagnostic), creatininemia (colorimetry,
Kone Optima, Thermolab System) and 24-hr urinary al-
bumin excretion rate (laser immunonephelometry,
BN100, Dade-Behring). The LDL cholesterol level was
calculated according to the Friedwald formula and the
creatinine clearance was assessed using the Modification
of Diet in Renal Disease (MDRD) study’s formula. Vas-
cular Cellular Adhesion Molecule (VCAM) was retro-
spectively measured according to the manufacturer’s
instructions (quantikine ELISA kit, R&D Systems,
Abingdon, UK), from samples stored at −80°C in the
Biological Research Centre of our hospital. Each sample
and standard protein was assayed in duplicate.
Statistical analyses
Sample size was calculated in order to allow a sufficient
power both to analyze differences between the different
categories of diabetic patients and between diabetic pa-
tients and obese or control subjects. Preliminary studies
[3,21,22] allowed considering that diabetic patients will
be distributed in proportions 4/3/1 regarding the 3 cat-
egories: no SMI/SMI without CAD/SMI with CAD.
Thus, considering a difference of 5% dilation of the bra-
chial artery between the group with SMI and CAD and
the 2 others and a standard deviation (SD) equal to 5%;
a cohort of 120 diabetic patients will allow a power
higher than 90% to detect a difference between the 3
groups using a two-sided 5% significance ANOVA level.
In addition a sample size of 30 control subjects and 30
obese patients will allow a 90% power to detect a 6% dif-
ference between these groups and the diabetic patients.
According to their Gaussian or non-Gaussian statis-
tical distribution, continuous variables were expressed as
means ± SD or median (upper limits of first and third
quartiles) and compared with parametric or non-
parametric (Kruskall-Wallis) ANOVA for the three
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groups’ comparison and with either t-tests or Mann–
Whitney tests with α-value adjusted for multiplicity by
Bonferroni method for two-by-two comparisons. The
significance of the differences in proportions was tested
with the x2 test. Logistic regression was used for multi-
variate analyses based on models including (i) the factors
that were associated with SMI (SMI-model 1) or asymp-
tomatic CAD (CAD-model 1) with a p value ≤ 0.10 in
univariate analyses, with in addition angiotensin conver-
sion enzyme (ACE)-inhibitors and (ii) factors that have
been previously reported to be associated with these
conditions (model 2: age ≥60 years, diabetes duration
≥10 years, male gender, retinopathy, nephropathy, per-
ipheral or carotid occlusive arterial disease, hyperten-
sion, dyslipidemia and smoking habits) [1-4].
The sensitivity, specificity, negative predictive value
and positive predictive value of paradoxical vasoconstric-
tion were assessed to diagnose SMI or silent CAD. Stat-
istical analyses were carried out using SAS software,
version 9.2 (SAS Institute). The 0.05 probability level
was considered for statistical significance.
Results
Subjects
Twenty-five control subjects, 30 overweight or obese pa-
tients and 118 diabetic patients were included, whose
characteristics are summarized in Table 1.
Flow mediated dilation measurements
FMD was measurable in all subjects and lower in the
diabetic patients than in control subjects and in over-
weight or obese patients, with also a higher rate of
paradoxical vasoconstriction (Table 1). This was also
true after adjustment on age and gender.
In the diabetic patients, deflation cuff induced a mean
increase in flow velocity of 288 (200;417)% and median
FMD was 0.6 (−1.2;3.2)%. A paradoxical vasoconstriction
was observed in 47 (39.8%) patients (Table 2) and associ-
ated with lower age (vasoconstriction vs no vasoconstric-
tion: 59.1 ± 9.3 vs 62.5 ± 7.2 years respectively, p < 0.05)
and HDL cholesterol levels (1.0 (0.8;1.2) vs 1.2 (1.0;1.3)
mmol/l, p < 0.01); and with higher HbA1c (7.9
(7.0;9.6)%; 63 (53;81) mmol/mmol) vs 7.4 (6.7;8.4)%; 57
(50;68) mmol/mmol; p < 0.05) and triglyceride (1.8
(1.2;2.5) vs 1.4 (1.0;1.8) mmol/l, p < 0.05) levels. The pa-
tients without paradoxical vasoconstriction were also
more likely to be treated with ACE-inhibitors (52.1 vs
31.9%, p < 0.05). There was no association between vaso-
constriction and VCAM levels or urinary albumin excre-
tion rate (Additional file 1: Table S1).
Screening for SMI and silent CAD in the diabetic patients
The characteristics of the 118 enrolled type 2 diabetic
patients are further shown in Table 2. Regarding
ALFEDIAM-SFC criteria, 47 (39.8%) of them fulfilled
non exclusively the “type 2 diabetes with cardiovascular
risk” criterion, 37 (31.4%) the “peripheral or carotid oc-
clusive arterial disease or macroproteinuria” criterion, 18
(15.2%) the “microalbuminuria with cardiovascular risk”
criterion, and 16 (15.4%) the “physical activity” criterion.
Nephropathy as defined by microalbuminuria or macro-
proteinuria affected 49 patients.
A myocardial scintigraphy was performed in 109 pa-
tients including 56 after ECG stress test, 39 after
Table 1 Characteristics of control subjects, overweight or obese patients and diabetic patients
Control group Overweight or obese patients Diabetic patients p
n = 25 n = 30 n = 118
Age, years 23 (22;25) 37 (31;49)* 61 (56;67)*† <0.01
Gender (male/female) 15/10 3/27* 72/46† <0.01
Body mass index, kg/m2 21.7 (20.4;23.0) 34.1 (31.3;37.1)* 30.0 (26.9;34.7)*† <0.01
Hypertension (%) NA 7 (23.3) 103 (87.3) <0.01
Dyslipidemia (%) NA 12 (40.0) 103 (87.3) <0.01
Total cholesterol, mmol/l 4.7 (4.4;5.5) 4.4 (3.8;5.2) 0.05
HDL cholesterol, mmol/l 1.21 (1.03;1.35) 1.08 (0.92;1.3) 0.06
LDL cholesterol, mmol/l 3.17 ± 0.90 2.65 ± 0.92 <0.01
Triglycerides, mmol/l 1.17 (0.90;1.79) 1.52 (1.10;2.20) <0.05
Smoking (%) NA 3 (10.0) 23 (19.5) NS
FMD, % 3.95 (1.43;5.25) 4.25 (1.74;5.56) 0.61 (−1.22;3.2)*† <0.01§
Paradoxical vasoconstriction (%) 3 (12) 3 (10.0) 47 (39.8)*† <0.01§
VCAM, ng/ml 485 (435;656) 562 (430;677) NS
Data are means ± SD or median (upper limits of first and third quartiles); *: p < 0.01 vs control subjects; †: p < 0.01 vs overweight or obese patients. §: also after
adjustment on age and gender.
FMD: flow mediated dilation, NA: non applicable, NS: non significant, VCAM: Vascular Cellular Adhesion Molecule.
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Table 2 Type 2 diabetic patients’ characteristics according to the presence or absence of silent myocardial ischemia
Total n = 118 No SMI n = 58 SMI n = 60 Univariate analysis Multivariate analysis*
p Odds ratio [95CI] p
Clinical characteristics
Age ≥60 years (%) 72 (61.0) 39 (67.2) 33 (55) NS
Age, years 61.1 ± 8.2 62.1 ± 7.9 60.2 ± 8.5 NS
Gender (Male/Female) 72/46 29/29 43/17 <0.05 NS
Body mass index, kg/m2 30.6 ± 5.4 31.6 ± 5.9 29.6 ± 4.7 <0.05 NS
Diabetes
Diabetes duration, years 13 (10;20) 14 (9;21) 13 (11;19) NS
Diabetes duration ≥10 years (%) 90 (76.3) 42 (72.4) 48 (80) NS
HbA1c, % 7.5 (6.8;8.7) 7.5 (6.8;8.5) 7.7 (6.8;8.8) NS
HbA1c, mmol/l 58 (51;72) 58 (51;69) 61 (51;73) NS
Retinopathy (%) 58 (51.3) 25 (45.5) 33 (56.9) NS
Nephropathy (%) 49 (41.5) 18 (31.0) 31 (51.7) <0.05 2.6 [1.2-5.7], p < 0.05
Creatinine clearance, ml/min 83 ± 22 84 ± 23 82 ± 21 NS
Urinary albumin excretion rate (mg/day) 17 (7;97) 11(6;54) 32 (12;277) NS
Macroproteinuria (%) 25 (21.4) 9 (15.5) 16 (27.1) NS
Peripheral neuropathy (%) 54 (45.8) 24 (41.4) 30 (50.0) NS
Additional cardiovascular risk factors:
Hypertension (%) 103 (87.3) 48 (82.8) 55 (91.7) NS
Anti-hypertensive treatment (%) 102 (86.4) 47 (81.0) 55 (91.7) 0.10 NS
Dyslipidemia (%) 103 (87.3) 48(82.8) 55(91.7) NS
HDL cholesterol, mmol/l 1.1 (0.9;1.3) 1.1 (1.0;1.3) 1.0 (0.8;1.3) 0.08 NS
Triglycerides, mmol/l 1.5 (1.1;2.2) 1.4 (1;1.8) 1.8 (1.1;2.4) 0.05 NS
LDL cholesterol, mmol/l 2.7 ± 0.9 2.5 ± 0.8 2.8 ± 1.0 NS
Smoking (%) 23 (19.5) 9 (15.5) 14 (23.3) NS
Peripheral or carotid arterial disease (%) 17 (14.5) 8 (14) 9 (15) NS
VCAM, ng/ml 562 (430;677) 564 (464;665) 555 (412;683) NS
Peripheral endothelial function:
Forearm mediated dilation, % 0.61 (−1.22;3.2) 1.64 (0;3.69) 0.12 (−2.3;1.58) <0.01
Paradoxical vasoconstriction (%) 47 (39.8) 17 (29.3) 30 (50.0) <0.05 2.7 [1.2-5.9], p < 0.05
Pharmacologic treatments
Statins (%) 88 (74.6) 41 (70.7) 47 (78.3) NS
Fibrates (%) 8 (6.8) 4 (6.9) 4 (6.7) NS
Platelet antiaggregants (%) 74 (62.7) 33 (56.9) 41 (68.3) NS
ACE-inhibitors (%) 52 (44.1) 25 (43.1) 27 (45) NS
ARBs (%) 52 (44.1) 24 (41.4) 28 (46.7) NS
Beta-blockers (%) 22 (18.6) 10 (17.2) 12 (20) NS
Calcium-channel blockers (%) 41 (34.7) 19 (32.8) 22 (36.7) NS
Sulfonylureas (%) 77 (65.3) 36 (62.1) 41 (68.3) NS
Metformin (%) 102 (86.4) 49 (84.5) 53 (88.3) NS
Thiazolidinediones (%) 33 (28.0) 14 (24.1) 19 (31.7) NS
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dipyridamole injection and 14 after both, whereas it was
unavailable or refused for 9 patients. Stress echographies
were contributive in 90/118 patients, because of poor
echogenicity in 28 patients. SMI was diagnosed in 60/
118 (50.8%) patients according to an abnormal scintiscan
(n = 24) or an abnormal stress echocardiogram (n = 25)
or both (n = 11). A coronary angiography was subse-
quently performed in 59 of the 60 patients with SMI,
and 21 of them (35.6%) had CAD, including one-vessel
disease (n = 15), two- and three-vessel disease (n = 3 for
both). A total of 81 patients had as planned both a myo-
cardial scintigraphy and a stress echography. In these 81
patients, SMI was diagnosed in 44 patients according to
abnormal scintigraphies in 13, abnormal stress echogra-
phies in 20 and both in 11 patients. A coronary angiog-
raphy was subsequently performed in 43 of the 44
patients with SMI, and 17 of them (39.5%) had CAD.
Association between peripheral flow mediated dilation
and ischemic status in the diabetic patients
Baseline brachial artery diameter did not differ signifi-
cantly in the 3 groups (patients without SMI: 3.68 ±
0.64 mm, with SMI but no CAD: 3.92 ± 0.64 mm; with
SMI and CAD: 3.78 ± 0.54 mm). Deflation cuff induced
an immediate and similar increase in flow velocity in the
3 groups (p = NS), as shown by the increase in velocities
at cuff deflation: no SMI 299 (211;443); SMI but no
CAD 290 (214;414); SMI and CAD 250 (150;413)%.
FMD was more impaired and the prevalence of para-
doxical vasoconstriction was higher in the diabetic pa-
tients with SMI than in those without (Table 2) and in
the patients with asymptomatic CAD than in those with-
out (Table 3). Figure 1 shows the values of FMD (panel
A) and the prevalence of paradoxical vasoconstriction
(panel B) in the patients without SMI, those with SMI
but no CAD, and those with both SMI and CAD. The
results were similar when only the 81 patients having
had both myocardial scintigraphy and stress echography
were considered: FMD 1.63 (0.00;3.59), 0.46 (−1.22;1.61)
and −1.22 (−3.8;0.25) (p < 0.01); paradoxical vasocon-
striction 27.0, 42.3 and 64.7%, (p < 0.05), in patients
without SMI, with SMI but no CAD and with both SMI
and CAD, respectively.
Factors associated with SMI and asymptomatic CAD
The factors associated with SMI were male gender, body
mass index, nephropathy, triglycerides levels, FMD and
paradoxical vasoconstriction (p < 0.05) with a trend for
HDL-cholesterol (p < 0.10) (Table 2). To explain SMI,
multiple logistic regression analyses were performed
with these parameters (SMI-model 1) and paradoxical
vasoconstriction. SMI was independently associated with
paradoxical vasoconstriction and nephropathy (Table 2).
When FMD instead of paradoxical vasoconstriction was
considered in the same model, FMD (odds ratio 0.86
[95% confidence interval 0.77-0.96], p < 0.01) and ne-
phropathy (OR 2.57 [1.17-5.63], p < 0.05) were independ-
ently associated with SMI. The results were also similar
when treatment with ACE-inhibitors was added to SMI-
model 1. FMD or paradoxical vasoconstriction was also
independently associated with SMI when the analyses
were restricted to the 81 patients having had both the
myocardial scintigraphy and the stress echography (data
not shown). With model 2 considering the factors previ-
ously associated with silent coronary status, the results
both for paradoxical vasoconstriction and FMD were
similar as the ones of SMI-model 1. Paradoxical vaso-
constriction had a sensitivity of 50.0%, a specificity of
70.7%, and positive and negative predictive values of re-
spectively 63.8% and 57.7%, to detect SMI.
The factors associated with asymptomatic CAD were
triglyceride levels, FMD and paradoxical vasoconstric-
tion, with a trend for body mass index, HDL and LDL
cholesterol levels and treatment with alpha glucosidase
inhibitors (Table 3). To explain asymptomatic CAD, a
multiple logistic regression analysis was performed with
these parameters (CAD-model 1) and paradoxical vaso-
constriction or FMD. CAD was associated only with
paradoxical vasoconstriction (Table 3) or with FMD (OR
0.83 [0.73-0.95], p < 0.01). The results were similar when
only the 81 patients having had both the myocardial
scintigraphy and the stress echography were considered
in CAD-model 1, for paradoxical vasoconstriction (OR
3.49 [1.07;11.44], p < 0.05) or FMD (OR 0.84 [0.72; 0.98],
p < 0.05). The results of multivariate analyses considering
the parameters included in model 2 with paradoxical
vasoconstriction or FMD were similar. Paradoxical vaso-
constriction had a sensitivity of 61.9%, a specificity of
Table 2 Type 2 diabetic patients’ characteristics according to the presence or absence of silent myocardial ischemia
(Continued)
Alpha-glucosidase inhibitors (%) 42 (35.6) 17 (29.3) 25 (41.7) NS
Insulin (%) 49 (41.5) 27 (46.6) 22 (36.7) NS
Data are means ± SD or median (upper limits of first and third quartiles); *: multivariate analysis taking into account the factors that were associated with silent
myocardial ischemia with a p value ≤ 0.10 in univariate analyses (SMI-model 1).
95CI: 95% confidence interval, ACE-inhibitor: angiotensin conversion enzyme, ARB: angiotensin II receptor blocker, FMD: flow mediated dilation, NS: non significant,
SMI: silent myocardial ischemia, VCAM: Vascular Cellular Adhesion Molecule.
Nguyen et al. Cardiovascular Diabetology 2014, 13:20 Page 6 of 11
http://www.cardiab.com/content/13/1/20
Table 3 Patients’ characteristics according to the presence or absence of asymptomatic coronary artery disease in the
diabetic cohort
No CAD n = 96 CAD n = 21 Univariate analysis Multivariate analysis*
p Odds ratio [95CI] p
Clinical characteristics:
Age, years 61.0 ± 8.1 62.0 ± 8.8 NS
Gender (Male/Female) 56/40 16/5 NS
Body mass index, kg/m2 31.0 ± 5.6 28.6 ± 3.9 0.07 NS
Diabetes:
Diabetes duration, years 14 (10;21) 12 (11;19) NS
HbA1c, % 7.5 (6.8;8.9) 7.7 (6.9;8.0) NS
HbA1c, mmol/mmol 58 (51;74) 61 (52;64) NS
Retinopathy (%) 47 (51.1) 11 (55.0) NS
Nephropathy (%) 38 (39.6) 11 (52.4) NS
Creatinine clearance, ml/min 83.6 ± 21.6 79.8 ± 24.2 NS
Urinary albumin excretion rate (mg/day) 14 (7;74) 32 (7;495) NS
Macroproteinuria (%) 18 (18.9) 7 (33.3) NS
Peripheral neuropathy (%) 45 (46.9) 9 (42.9) NS
Additional cardiovascular risk factors:
Hypertension (%) 83 (86.5) 19 (90.5) NS
Anti-hypertensive treatment (%) 82 (85.4) 19 (90.5) NS
Dyslipidemia (%) 83 (86.5) 19 (90.5) NS
HDL cholesterol, mmol/l 1.1 (1.0;1.3) 1.0 (0.8;1.0) 0.08 NS
Triglycerides, mmol/l 1.5 (1.1;2.1) 2.0 (1.4;2.5) <0.05 NS
LDL cholesterol, mmol/l 2.6 ± 0.8 3.0 ± 1.2 0.10 NS
Smoking (%) 18 (18.8) 5 (23.8) NS
VCAM, ng/ml 549 (422;665) 621 (526;712) NS
Peripheral endothelial function:
Forearm mediated dilation, % 1.13 (−0.4;3.28) −1.22 (−2.5;1.0) <0.01
Paradoxical vasoconstriction (%) 33 (34.4) 13 (61.9) <0.05 3.1 [1.2-8.2], p < 0.05
Pharmacologic treatments
Statins (%) 72 (75) 15 (71.4) NS
Fibrates (%) 5 (5.2) 3 (14.3) NS
Platelet antiaggregants (%) 58 (60.4) 15 (71.4) NS
ACE-inhibitors (%) 46 (47.9) 6 (28.6) NS
ARBs (%) 39 (40.6) 12 (57.1) NS
Beta-blockers (%) 17 (17.7) 5 (23.8) NS
Calcium-channel blockers (%) 31 (32.3) 10 (47.6) NS
Sulfonylureas (%) 65 (67.7) 11 (52.4) NS
Metformin (%) 83 (86.5) 18 (85.7) NS
Thiazolidinediones (%) 26 (27.1) 7 (33.3) NS
Alpha-glucosidase inhibitors (%) 38 (39.6) 4 (19) 0.08 NS
Insulin (%) 38 (39.6) 10 (47.6) NS
Data are means ± SD or median (upper limits of first and third quartiles); *: multivariate analysis taking into account the factors that were associated with coronary
artery disease with a p value ≤ 0.10 in univariate analyses (CAD-model 1).
95CI: 95% confidence interval, ACE-inhibitor: angiotensin conversion enzyme, ARB: angiotensin II receptor blocker, CAD: coronary artery disease, FMD: flow
mediated dilation, NS: non significant, VCAM: Vascular Cellular Adhesion Molecule.
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65.6%, and positive and negative predictive values of re-
spectively 28.3% and 88.7%, to detect asymptomatic
CAD.
Discussion
We confirmed that peripheral FMD is impaired in type
2 diabetes, as compared to control subjects and non-
diabetic obese patients. In particular, we report here for
the first time that FMD is independently associated with
SMI; and even more specifically when ischemia is associ-
ated with CAD on angiography. This was observed while
the immediate post-ischemic flow increase, a surrogate
for microcirculation, remained similar whatever the
heart ischemic status in these diabetic patients.
In the present study, the mean FMD was around 4% in
control subjects and overweight/obese patients, and 1%
in diabetic patients. The fact that FMD was lower in
diabetic patients than in non-diabetic obese subjects
shows that obesity per se did not affect FMD and that
diabetes plays a major role in the impairment of FMD.
FMD was lower than the levels reported elsewhere. In-
deed, the normal values of FMD have not been well-
established in a control population and are widely vari-
able according to methods for measurements [19]. Bots
et al. have reviewed more than 200 papers from 1992 to
2001 and reported in healthy subjects FMD from 0.2 to
19.2% and in diabetic patients from 0.75 to 12% [23]. In
their conclusion technical aspects of measurements, lo-
cation and duration of occlusion may explain some of
the differences while type of equipment, location of
measurement and occlusion pressure do not. Our local
control groups had low FMD but our results in our dia-
betic cohort may also be explained by long standing dia-
betes and a high a priori cardiovascular risk, due to our
A
29.3
42.1
61.9
0
10
20
30
40
50
60
70
No SMI SMI without CAD SMI and CAD
p<0.05B
No SMI SMI without CAD SMI and CAD
30
20
10
0
- 10
- 20
Fl
ow
 m
ed
ia
te
d 
di
am
et
er
 c
ha
ng
es
  (%
)
p<0.01
*
**
Pa
ra
do
xi
ca
l
Va
so
co
ns
tr
ic
tio
n 
(%
)
Figure 1 Peripheral endothelial function according to silent myocardial ischemia and coronary artery disease status. Flow mediated
dilation (Panel A) and paradoxical vasoconstriction (panel B) in patients without silent myocardial ischemia (no SMI), with SMI but no coronary
artery disease (SMI, no CAD) and with CAD (SMI and CAD). * p < 0.05 and ** p < 0.01 vs patients without SMI.
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inclusion criteria. For example, the prevalence of asymp-
tomatic CAD was high in our cohort (17.8%), whereas
we previously reported a lower prevalence (10-15%) in
patients with type 2 diabetes who were screened for SMI
only by stress scintigraphy [7,21,22] instead of two tests
in the present study. FMD may be considered as an inte-
grator of cardiovascular risk, i.e. a marker of cardiovas-
cular stress related to the presence of risk factors and
their levels, whatever the underlying mechanism. In the
present study, paradoxical vasoconstriction was associ-
ated with a more impaired lipid profile, a poorer gly-
cemic control, less current treatment by ACE-inhibitors,
and a trend for smoking, despite a lower age.
FMD studies explore the peripheral vasculature re-
sponse to transient ischemia. The flow response, as
depicted by the flow velocity increase after cuff deflation,
reflects the distal microcirculation response to ischemia,
and an impaired response has been reported to predict
cardio-vascular events [24]. Diameter changes after the
increase in flow depend on the endothelium, mainly
through a nitric oxide-dependent mechanism, but also
on vascular smooth muscle cell contraction/relaxation.
Endothelial dysfunction may be considered as a cardio-
vascular risk factor or at least as a cardiovascular risk
marker [12,25], but impairment of vascular smooth
muscle cell function has been also reported in diabetic
patients [9] and may be involved in altered FMD. The
mechanism of impaired FMD cannot be explained in
our results since we did not test specifically vascular
smooth muscle cell function, like Peix et al. [14]. The
absence of significant difference between patients who
constricted their brachial artery and those who did not
for VCAM and albuminuria, which are usually consid-
ered as endothelium markers [26], might be consistent
with the role of impaired smooth muscle cell function in
our population. The important fact is that an impaired
FMD response per se, whatever its mechanism, was
shown to predict a poor cardio-vascular prognosis in
several large population studies [25,27].
Abnormal coronary vasomotion [10,28] and coronary
endothelial dysfunction [29] are also associated with a
poor cardiovascular prognosis in diabetes. A direct rela-
tionship between peripheral and coronary vascular func-
tion may be difficult to demonstrate. FMD was reported
to statistically correlate with coronary response to
acetylcholine, but this correlation was weak [30]. Gori
et al. recently showed that using FMD provides signifi-
cant additional information in predicting the presence of
CAD in patients suffering from angina [31]. Further-
more, FMD has recently been shown to be independ-
ently associated with slow coronary flow in patients with
angina and non significant narrowed CAD [32]. Al-
though, we have clearly demonstrated here that an al-
tered FMD was independently associated with SMI,
other studies failed to show a strong association between
FMD and SMI. This discrepancy seems to be related to
the difference in the cardiovascular risks of the patients
in these studies compared to our study population
(Table 2: diabetes duration 13 years, hypertension and
dyslipidemia in 87.3% and smoking in 19% of the pa-
tients). In the Detection of Ischemia in Asymptomatic
Diabetics (DIAD) study, FMD was measured in 75
asymptomatic type 2 diabetic patients and was found to
be similar in those with or without SMI [13]. The car-
diovascular risk profile was better than in our study
population, with a mean diabetes duration of 8.4 years,
and hypertension, dyslipidemia and smoking habits in
49%, 59% and 8% of the patients, respectively, and only
15 (20%) of the patients had SMI. When the cardiovas-
cular risk profile of the patients was intermediate as in
Peix et al. study (diabetes duration 11 years, age 58
years, hypertension, dyslipidemia and smoking habits in
77%, 73% and 32% of the patients, respectively), there
was a higher prevalence of abnormal FMD in those with
SMI as compared with those without, whereas no differ-
ence was found for the mean values of FMD [14]. As re-
ported by Naka et al., duration of diabetes appears to be
an important factor for developing impaired FMD [33].
In these two studies performed in diabetic patients, cor-
onary status was not determined by angiography. This is
a crucial issue as SMI actually includes two entities: only
30-70% of the patients with SMI have significant CAD
[3] while ischemia in patients without CAD may result
from functional disorders [16], such as abnormal coron-
ary reserve or coronary endothelial dysfunction. In our
study population, 35% of the patients with SMI had
CAD. We report for the first time that the flow-
mediated vascular response was worse, with more para-
doxical vasoconstriction, when SMI or CAD were
present. Abnormal FMD was gradually further impaired
in the patients without SMI, with SMI but no CAD, and
with both SMI and CAD (Figure 1). This result is con-
sistent with the role of silent coronary disease in the
poorer prognosis associated with lower FMD in the dia-
betic population.
The use of FMD as a screening test for SMI was tested
in the DIAD study [13]. The negative predictive value
for SMI of a normal FMD was 93%. FMD was consid-
ered as abnormal when <8% i.e. at the threshold that
maximized the negative predictive value and had the
least impact on sensitivity while the study did not in-
clude control subjects. The threshold that we considered
in the present study was lower (<0%, i.e. paradoxical
vasoconstriction) and was in line with the high cardio-
vascular risk of our patients. We found that paradoxical
vasoconstriction was independently associated not only
with SMI but also with CAD. However, while the pres-
ence of a paradoxical vasoconstriction had an 88.7%
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negative predictive value for CAD, the positive predictive
value for CAD was too low to suggest the inclusion of
this criterion in the algorithm of CAD screening.
The present study has some limitations. The control
groups were not matched for gender, and by definition
age and BMI were different in the three groups of pa-
tients (healthy controls, non-diabetic obese patients and
diabetic patients). However, FMD was lower in the dia-
betic patients even after adjustment on age and gender.
Due to obvious ethical issues, no coronary angiography
was performed in the patients without SMI, and some
patients with CAD but no SMI may have been missed.
Furthermore, the cut-off for significant epicardial CAD
we used was 70% stenoses, whereas stenoses are now-
adays considered as significant with milder stenoses (i.e.
50% or more) when abnormal fractional flow reserve is
observed. However, in our study, these measurements
were not available for all the patients. Our FMD cutoff
of 0% may not be applicable to diabetic patients with a
low a priori cardiovascular risk. Lastly, we could not
distinguish whether abnormal FMD resulted from
endothelium-dependent or -independent disorders as
nitroglycerin-induced vasodilation was not tested.
Conclusions
Our results show in a cohort of asymptomatic type 2
diabetic patients with a high cardiovascular risk that im-
paired forearm FMD with a paradoxical vasoconstriction
is associated with SMI and CAD. However the present
data cannot lead to suggest FMD as a screening test for
silent CAD.
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